|
Q4 FY2026
As of Jul 31, 2026
|
Q3 FY2026
As of Apr 30, 2026
|
Q2 FY2026
As of Jan 31, 2026
|
Q1 FY2026
As of Oct 31, 2025
|
Q4 FY2025
As of Jul 31, 2025
|
Q3 FY2025
As of Apr 30, 2025
|
Q2 FY2025
As of Jan 31, 2025
|
Q1 FY2025
As of Oct 31, 2024
|
Q4 FY2024
As of Jul 31, 2024
|
Q3 FY2024
As of Apr 30, 2024
|
Q2 FY2024
As of Jan 31, 2024
|
Q1 FY2024
As of Oct 31, 2023
|
Q4 FY2023
As of Jul 31, 2023
|
Q3 FY2023
As of Apr 30, 2023
|
Q2 FY2023
As of Jan 31, 2023
|
Q1 FY2023
As of Oct 31, 2022
|
Q4 FY2022
As of Jul 31, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||||||||
| CURRENT ASSETS: | |||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||
| Amounts receivable | |||||||||||||||||
| Prepaid expenses | |||||||||||||||||
| Short-term investments | |||||||||||||||||
| Amounts receivable and prepaid expenses | |||||||||||||||||
| Total current assets | |||||||||||||||||
| NON-CURRENT ASSETS: | |||||||||||||||||
| Investments | |||||||||||||||||
| Equity investment in BC Therapeutics | |||||||||||||||||
| Intangible assets, net | |||||||||||||||||
| Property and equipment, net | |||||||||||||||||
| Long term prepaid expenses | |||||||||||||||||
| Total non-current assets | |||||||||||||||||
| Total assets | |||||||||||||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | |||||||||||||||||
| CURRENT LIABILITIES: | |||||||||||||||||
| Trade payables | |||||||||||||||||
| Accrued expenses and other payables | |||||||||||||||||
| Total current liabilities | |||||||||||||||||
| NON-CURRENT LIABILITIES: | |||||||||||||||||
| Warrant liability | |||||||||||||||||
| Total non-current liabilities | |||||||||||||||||
| SHAREHOLDERS’ EQUITY (DEFICIT): | |||||||||||||||||
| Share Capital of no par value – Authorized: unlimited at July 31, 2026 and 2025; Issued and outstanding: 8,708,029 and 1,883,906 shares at July 31, 2026 and 2025, respectively | |||||||||||||||||
| Additional paid in capital | |||||||||||||||||
| Share-based payment reserve | |||||||||||||||||
| Warrant reserve | |||||||||||||||||
| Accumulated other comprehensive loss | |||||||||||||||||
| Non-controlling interest | |||||||||||||||||
| Accumulated deficit | |||||||||||||||||
| Total shareholders’ equity | |||||||||||||||||
| Total liabilities and shareholders’ equity | |||||||||||||||||
Loading...